High Dose Fulvestrant reduces tumor growth
 

SAN ANTONIO, TX -- December 14, 2007 -- A high dose regimen of fulvestrant significantly reduces levels of an important marker of tumor growth compared with the approved 250 mg dose, according to data from a phase 2 study of neoadjuvant treatment presented here at the 30th Annual San Antonio Breast Cancer Symposium (SABCS).

to read full article:

http://www.docguide.com/news/content...2573B1004CD35F